Metformin and risk factors for chronic kidney disease in a European population based on Mendelian randomization
Background Metformin, widely used for type 2 diabetes, raises concerns about its use in chronic kidney disease (CKD) due to risks like lactic acidosis and renal function impact. This study uses Mendelian randomization (MR) and summary data-based MR (SMR) to explore metformin’s potential causal relat...
Saved in:
| Main Authors: | Xiaopei Liu, Xingyao Li, Peng An, Qi Gao, Yanhong Zhao, Xingmin Shi, Xili Wu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2025.2486551 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metformin and the risk of malignant tumors of digestive system: a mendelian randomization study
by: Ping Liu, et al.
Published: (2025-01-01) -
Metformin reduces the risk of frailty: evidence from a Mendelian randomization study
by: Tong Chen, et al.
Published: (2025-06-01) -
Unravelling the association between metformin and pan-cancers: Mendelian randomization combined with NHANES database analysis
by: Jia-Cheng Xiang, et al.
Published: (2025-03-01) -
Metformin and Risks of Aortic Aneurysm and Aortic Dissection: A Mendelian Randomization Study
by: Lei Wang, et al.
Published: (2025-04-01) -
Identification of Therapeutic Targets for Hyperuricemia: Systematic Genome-Wide Mendelian Randomization and Colocalization Analysis
by: Na Chen, et al.
Published: (2025-04-01)